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Prior studies on the transcription of erythrovirus B19 have identified a short leader sequence associated with all spliced
viral transcripts. While some variability has been observed in the acceptor for this first intron, studies to date in both
permissive and nonpermissive cell types have reported a unique splice donor site. In the semipermissive MB-02 cell line, we
have found that splicing of this first intron proceeds almost exclusively via a cryptic CT donor downstream of the previously
reported GT donor at nucleotide 406. The resulting messages for the viral structural proteins and 11-kDa protein are thereby
made bicistronic, with the first expressible polypeptide being a 34 amino acid fusion of the NS-1 and 7.5-kDa proteins. The
presence of an upstream open-reading frame on these messages is likely to block effective translation of the downstream
structural protein products. We propose this as a significant mechanism in determining B19’s tropism on the basis of host
cell splicing machinery, and present evidence in support of this model. Additionally, this is the first report of usage of a
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INTRODUCTION
Erythrovirus (human parvovirus) B19 is the causative
agent of the common childhood illness erythema infec-
tiosum (Anderson et al., 1983), as well as a number of
other less common conditions including fetal hydrops
(Brown et al., 1984) and miscarriage (Knott et al., 1984),
ransient aplastic crises (Saarinen et al., 1986), and tran-
ient postinfection arthropathy (White et al., 1985). In
ommon with other parvoviruses, the virus has a small,
nenveloped, icosahedrally symmetric capsid and a sin-
le-stranded DNA genome of approximately 5.6 kb (As-
ell et al., 1997). Two major open-reading frames are
ncoded, with that on the left of negative-strand ge-
omes coding for the viral nonstructural protein NS-1
nd that on the right coding for two structural proteins,
P-1 and VP-2. The two structural proteins are encoded
y the same reading frame such that VP-2 is completely
ontained within VP-1, and differential expression of the
wo depends on alternative splicing to select the initia-
ion codon (Ozawa et al., 1987). In addition, B19 has
oding potential for two small polypeptides, one of 7.5
Da around the middle of the genome and one of 11 kDa
ear the extreme right side (St. Amand et al., 1991).
pliced transcripts carrying these small open-reading
rames have been found to be abundant in infected cells
nd expression of both proteins has been detected by
1 To whom reprint requests should be addressed at current address:
epartment of Biochemistry and Molecular Biology, 2146 Health Sci-p
l
nces Mall, University of British Columbia, Vancouver, BC V6T 1Z3,
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estern blot, immunoprecipitation, and immunofluores-
ence studies of both infected human leukemic and
ransfected COS-7 cell systems; however, the biological
ignificance of these polypeptides remains unclear (As-
ell et al., 1997; St. Amand et al., 1991; Luo et al., 1993).
wo previous studies (Ozawa et al., 1987; St. Amand et
l., 1991) have examined the transcriptional map of B19,
hich is unique among parvoviruses in using a single
romoter to drive differential expression of nonstructural
nd structural genes via differential splicing (as summa-
ized briefly in Fig. 5A). While these two previous studies,
ncorporating both permissive and nonpermissive cell
ypes, demonstrated some minor differences in splice
ite usage between the cell types none of the differences
ere of significance with regard to coding potential of
he structural gene or 11-kDa mRNAs. Both studies ob-
erved that all spliced messages (that is, all encoding
nything other than the NS-1 protein) start with a 56-bp
eader sequence corresponding to viral nt 350 through
06 (nucleotide numbering throughout this report follows
he scheme of Shade et al. (1986).
B19 demonstrates a markedly restricted host range,
ith fully permissive infections only occurring in late
rythroid cell precursors and burst-forming erythroid pro-
enitors (BFU-E) (Mortimer et al., 1983). Culture of the
irus is generally limited to growth-factor stimulated
one marrow aspirates (Srivastava et al., 1988; Ozawa et
l., 1986) or to fetal cord blood (Sosa et al., 1992; Srivas-
ava et al., 1992) or to similarly treated “semipermissive”
ell lines such as MB-02 which allow for very limited viral
roduction (Munshi et al., 1993). While some other cell
ines of erythroid lineage have been shown to allow for
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US B1viral attachment, entry, and apparently normal viral
mRNA expression as judged by Northern blot analysis
(UT7 cells (Leruez et al., 1994)), or at least to allow
function of the viral promoter (K562 cells (Gareus et al.,
1998)) these cell lines do not appear to support produc-
tive replication (in the case of UT7 cells, some authors
have reported very low levels of virus production (Shi-
momura et al., 1992)). The mechanism(s) behind this
block in replication have not been elucidated, but one
suggestion has been a block in transcript maturation,
specifically in active 39 processing and recognition of
olyadenylation signals (Liu et al., 1992).
In this study we report our observation that the splic-
ng of the first viral intron is altered in MB-02 cells such
hat the leader sequence associated with all spliced
ranscripts does not generally end at nt 406 as previously
bserved. The vast majority of spliced transcripts in this
ystem instead have a leader extending to viral nt 441,
nd utilize a CT splice-donor nucleotide pair in conjunc-
ion with the previously reported nt 2030 AG acceptor for
he first intron. These messages thus contain a short
pen-reading frame (ORF) upstream of their proper mes-
age and, in the lack of a functional internal ribosomal
ntry site (IRES), result in an effective block in the trans-
ation of viral structural proteins required for productive
nfection.
RESULTS
While setting up a system for the detection and anal-
sis of B19 transcription in patient samples, we chose to
se infection of the semipermissive MB-02 cell line as a
ontrol source of viral transcripts. In order to minimize
he risk of false positive RT-PCR products arising from
otential contaminating viral DNA in RNA isolates, prim-
rs B19L2 and B19S2O were designed to span the viral
irst intron as based on published B19 transcription
aps. A third primer B19S2I was designed to anneal just
TABLE 1
Predicted B19 Amplicon Sizes
Template
First-round
(RT-PCR)
product
expected, bp
Second-round
(seminested PCR)
product
expected, bp
Unspliced pre-mRNA or DNA 1702 1686
1910 acceptor 199 183
2030 acceptor 79 63
1925 acceptor 184 168
1952 acceptor 157 141
Note. Predicted sizes of amplicons derived from B19 templates
described in the literature. All sizes are calculated based on usage of
the nt 406 splice donor for the viral first intron, and acceptors as noted.
SPLICING PATTERN IN PARVOVIRpstream of B19S20 and be used with B19L2 for semin-
sted reamplification of weak first-round products.Based on previously published results, a single splice
donor at nt 406 is used for this first viral intron, with some
variability observed in choice of splice acceptor. In per-
missive cells, splice acceptors at nt 2030 and nt 1910 are
reported, with that at nt 1910 being more commonly used
Ozawa et al., 1987). In the nonpermissive COS-7 system,
plice acceptors in the small viral mRNAs coding for the
.5- and 11-kDa proteins have been reported at nt 1925
nd nt 1952 in addition to nt 1910 and nt 2030 (St. Amand
t al., 1991). Our primer set was designed to amplify all of
hese alternative products. The expected first (RT-PCR)
nd second (seminested PCR) amplicon sizes for these
ifferent possible templates are shown in Table 1.
As a control, we also designed a set of primers to
mplify the cellular retinoblastoma mRNA with primers
panning intron 7 of the gene. These primers were de-
igned to have similar annealing temperature and prod-
ct amplicon sizes as the B19 primers used in the study.
s for the B19 system, a total of three primers (Rb1, Rb20,
nd Rb2I) was designed to be used in RT-PCR and
ubsequent seminested PCR amplification of templates.
he expected product sizes from mature spliced mes-
age or from DNA or unspliced pre-mRNA templates are
iven in Table 2.
Following infection of differentiated MB-02 cells with
19 and RNA isolation we performed RT-PCR and the
eminested PCR as described on the RNA extracts. As
hown in Fig. 1, the RT-PCR for the cellular retinoblas-
oma message proceeded cleanly and yielded a single
roduct at the expected size (lane 2). Results of a semi-
ested second round reaction were also as predicted
data not shown; as the products of the RT-PCR were
learly visible this was generally not conducted). RT-PCR
or B19 message (lane 4) yielded a single strong unpre-
icted product of approximately 115 bp, as well as a very
uch weaker mixture of poorly resolving bands in the
50–200 bp size range corresponding to a mixture of
ome of the predicted amplicon products. Second-round
eminested PCR amplification of these RT-PCR products
etained all of these bands with the expected decrease
n length of each product (lane 5). Successful second-
ound amplification indicated that all of these products,
TABLE 2
Predicted Retinoblastoma Amplicon Sizes
Template
First-round
(RT-PCR)
product
expected, bp
Second-round
(seminested PCR)
product
expected, bp
Unspliced pre-mRNA or DNA ;1800 ;1800
spliced mRNA 175 121
2859 RESTRICTS ITS HOST RANGENote. Predicted sizes of amplicons derived from retinoblastoma
templates, based on data of McGee et al. (1989).
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¨ D-VENincluding the major unexpected product, were derived
from B19 sequence.
In order to determine if the unexpected product could
potentially be amplified from some viral DNA species
such as defective interfering genomes, we attempted an
identical set of amplifications for B19 products using
viremic patients directly as the template. As shown in
Fig. 2, the RT-PCR (lane 2) only yielded one distinct
product, which is the predicted 1.7 kb size for amplifica-
tion with this primer set from viral DNA. No products in
the 100–200 bp size range are observed. Upon reampli-
fication with the seminested PCR (lane 3), the full-length
genomic-derived product was not reamplified due to a
very short extension time in the thermocycling (optimized
to favor short products). Only faint diffuse products were
visible in the second-round reaction with most being
approximately 500 bp in length; these are likely to be a
FIG. 1. RT-PCR and seminested PCR on RNA extracts of B19-infected
B-02 cells. Products of RT-PCR and seminested second-round PCR
n RNA extracts of B19-infected differentiated MB-02 cells as analyzed
y 2% agarose gel electrophoresis and ethidium bromide staining of
0-ml reaction samples. Left panel: RT-PCR for retinoblastoma mRNA
(Lane 2). Right panel: RT-PCR for B19 mRNA (Lane 4) and subsequent
seminested PCR (Lane 5); Lane 6 is product of the second-round PCR
for B19 without template added. Lanes 1 and 3 are 100-bp DNA ladder
with sizes as marked.
FIG. 2. RT-PCR and PCR results on viremic serum-derived nucleic
acids. RT-PCR amplification (Lane 2) and seminested second-round
PCR (Lane 3) on serum control, analyzed by 2% agarose gel electro-
phoresis and ethidium bromide staining of 10-ml reaction samples.
286 BRUNSTEIN, SODERLUNLane 4 is a PCR on same template using p8f/p5r primer set; Lane 5 is
a p8f/p5r no template (2) control. Lanes 1 is a 100-bp ladder.range of single-stranded products arising from nonexpo-
nential extension of both first- and second-round primer
sets off B19 DNA present in the sample. In contrast,
amplification of an identical template sample with primer
set p8f/p5r under conditions very similar to those used in
the second-round reactions yielded a single sharp prod-
uct band of expected size (393 bp, lane 4) and demon-
strated the presence of amplifiable B19 DNA in the sam-
ple.
To further examine whether the unexpected major
product was amplified from an RNA template, we pre-
treated samples of RNA from infected MB-02 cell culture
with RNase A prior to RT-PCR amplification. As shown in
Fig. 3, the RNase predigestion completely abolished am-
plification of both the retinoblastoma control target and
all B19 targets. Based on this and the previous experi-
ment, we concluded that the template for the unexpected
product was in fact an RNA species apparently of viral
origin.
Prior studies which generated the available viral tran-
scription maps had demonstrated some variability in the
acceptor site for the splicing of the viral first intron which
our amplicon should span. A total of four acceptors has
been observed in all cell types, at nts 1910, 1925, 1952,
and 2030, and in all cases the acceptor is a canonical AG
splice acceptor dinucleotide. As this variability suggests
some lack of precision in recognition of this splice ac-
ceptor by cellular machinery, we examined the viral se-
quence between nt 1910 and nt 2030 for other potential
AG splice acceptor sites whose usage might result in a
message serving as template for our observed major
product. A total of 13 AG dinucleotides was found in this
region in the B19-Au reference sequence (GenBank Ac-
cession Number M13178), including the four already
FIG. 3. Effect of RNase A treatment of templates prior to RT-PCR. RNA
extracts from infected MB-02 cells were either pretreated with RNase
A (Lane 3) or left untreated (Lane 2) prior to RT-PCR amplification for
B19 (upper panel) or retinoblastoma (lower panel) mRNAs. Product
amplification in both cases is only observed in the absence of RNase
ERMO, AND HEDMANdigestion. Results shown are of agarose gel electrophoresis and
ethidium bromide staining of 10-ml reaction samples.
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oknown to act as splice acceptors. In order to examine
whether our product arose from a message using one of
these sites, we gel-isolated our observed major RT-PCR
product and performed DNA sequencing of it. As shown
in Fig. 4A, results of this demonstrate that the product in
fact had arisen from an RNA species in which the first
intron is indeed spliced in a novel manner; however,
contrary to our preliminary expectations, it is the splice
donor site (at nt 441) and not the splice acceptor (at nt
2030) which differs from published transcription maps.
Based on these observed splice boundaries, the ex-
pected size of our first-round (RT-PCR) amplicon is 114
bp and that of the second round (seminested PCR) is 98
bp; these values agree well with their observed sizes in
agarose gel electrophoresis (see Fig. 1, lanes 4 and 5).
Based on the Au reference sequence for B19 (Shade et
al., 1986), the splice donor in this case is an unusual CT
base pair. In order to check whether this held true for the
virus present in our infectious serum, the majority of the
viral genome was cloned from the same serum sample
used for infecting cells in previous experiments (see
Materials and Methods). We sequenced the genomic
region in question and found that our viral genome
agreed with the Au reference for these nucleotides; the
splice donor for our observed major intron is thus a “CT”
dinucleotide. Over the total region we sequenced (.600
FIG. 4. Partial sequence of the major amplified product and its transla
rom B19 RT-PCR as described. Nucleotide numbers above the sequ
ucleotide numbering of Shade et al. (1986). Inferred translational produ
equence. (B) Sequence of the genomic splice donor and splice acce
unction is indicated by “/”. (C) Full translational potential of the open-re
f the splice junctions observed in this study.
SPLICING PATTERN IN PARVOVIRnt; submitted to the GenBank nucleotide sequence da-
tabase and assigned Accession Number AF272985) we mobserved better than 98% identity with other B19 se-
quences in GenBank, suggesting that our infectious se-
rum does not represent an unusual strain.
DISCUSSION
Human parvovirus B19 has a remarkably narrow host
range limited to a subset of erythroid lineage cells in-
cluding burst-forming and colony-forming erythroid pro-
genitors from bone marrow, fetal liver, chronic myeloge-
nous leukemia, erythroleukemia, and peripheral blood
(for review, see Astell et al., 1997). While all of these can
be used as primary cultures for virus propagation in the
laboratory, they require addition of expensive growth
factors and are inconvenient to handle. Efforts to identify
a continuous cell line culture system have met with little
success (Brown et al., 1994); the megakaryoblastoid
lines MB-02 and UT-7 have both been shown to have
very limited capacity to support viral replication in the
presence of growth factors. To date these are the most
convenient system for viral culture; however, a very re-
cent report (Miyagawa et al., 1999) suggests that a newly
isolated cell line, KU812Ep6, may afford an improved
culture system. A major cause of restricted viral tropism
appears to be an inability of the viral p6 promoter to
function in nonerythroid cells (Kurpad et al., 1999; Pon-
otential. (A) Sequence data obtained from the major amplified product
indicate the position of specific nucleotides relative to the genomic
this part of the sequence are given by one-letter code beneath the DNA
es. Twenty nucleotides to either side of the junction are given; splice
frame created by fusion of the NS-1 ORF to the 7.5-kDa ORF by usage
2879 RESTRICTS ITS HOST RANGEtional p
ence
cts for
ptor sit
US B1nazhagen et al., 1995). Other similar cell lines which
ight be expected to support viral growth, such as K-562
e
t
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onor a
r served
2 ¨cells with or without treatment to induce erythroid differ-
entiation, do not allow for detectable productive viral
replication (M. So¨derlund-Venermo and J. Brunstein, un-
published observations), despite apparently normal ca-
pacity to support expression of the viral p6 promoter
(Gareus et al., 1998). On the basis of observed differ-
nces in accumulation of structural versus nonstructural
ranscripts in permissive and nonpermissive cell types,
iu et al. have suggested that differences in active 39
processing of viral pre-mRNAs may account in part for
viral tropism, with nonpermissive cell types overproduc-
ing message for the nonstructural gene relative to struc-
tural gene mRNAs (Liu et al., 1992). As there is good
evidence to suggest the nonstructural gene product
NS-1 is cytotoxic (Moffat et al., 1998), this is proposed to
cause cell death before productive replication has oc-
curred. While such a model has merits, it is somewhat
unsatisfying as it predicts that at least low levels of viral
structural protein should be expressed and suggests
that correspondingly low levels of infectious progeny
virions should be liberated. More recently, it has been
shown that the 39 untranslated region of spliced viral
messages is capable of inhibiting its own translation in
some nonpermissive cell types (HeLa, COS-7) by block-
ing ribosome loading (Pallier et al., 1997), although the
basis for this has not been elucidated. Thus, to date no
convincing mechanism has been put forward to account
for B19’s limited tropism and its lack of replication in cells
which support viral entry and expression.
We report here on studies conducted in the MB-02 cell
FIG. 5. Previous and proposed variant transcriptional maps. Multiple l
intron sequences, and solid thick lines indicate open-reading frames o
families after Ozawa et al. (1987) and St. Amand et al. (1991), with d
epresentation of the same transcripts as resulting from the splicing ob
88 BRUNSTEIN, SODERLUNline. Prior studies have demonstrated that following dif-
ferentiation in growth-factor-supplemented media, thiscell line produces viral mRNAs (as shown by Northern
blot) and low levels of infectious progeny virions as
demonstrated by their ability to be passaged and infect
normal bone marrow cells (Munshi et al., 1993). While
attempting to use this culture system as a source of
standard B19 mRNAs, we have observed that in viral
messages which incorporate a spliced first intron (that
is, all messages other than that coding for the viral
nonstructural protein) the vast majority of such splices
utilize a novel splice donor site at nt 441 in conjunction
with the previously known major acceptor at nt 2030, and
thereby alter the viral transcriptional map. Examination of
the coding potential of these altered messages shows
that this splicing pattern fuses the initiating and second
codon of the nonstructural protein gene in frame with the
32 C-terminal residues of the poorly characterized 7.5-
kDa protein ORF (see Fig. 4B). In doing so it makes all
spliced viral messages bicistronic, with this short NS-1/
7.5-kDa fusion ORF being the 59 member of the pair
(Fig. 5).
Rather than producing a single genomic mRNA spe-
cies and translating all protein products from that via
usage of an IRES, or a polyprotein expression scheme as
used by some other viruses, evidence to date suggests
that B19 uses differential splicing to generate monocis-
tronic mRNAs for each of its expressed proteins as its
only protein expression tactic. The levels of each specific
mRNA, as determined by differential splicing, in turn
control the levels of the different protein products. Some
evidence in the literature exists that in the case of the
icates noncoding regions of mature mRNA, thin dashed lines indicates
e mRNA; “mu” is map units. (A) Simplified schematic of B19 transcript
nd acceptor sites for the first viral intron as marked. (B) Equivalent
in this report. The 39 terminii of these messages are inferred from A.
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D-VENviral 11-kDa message, three very closely spaced AUG
codons in the same frame at the start of the message
US B1may each act as an initiation codon (St. Amand et al.,
1991); however, aside from that example there appears to
be no evidence for initiation of translation from anything
but the first in-frame AUG of viral mRNAs. In particular,
VP-1 and VP-2 are coded for in the same frame with VP-1
containing all of VP-2 plus additional N-terminal resi-
dues; yet translation of VP-2 does not appear to occur
from VP-1 mRNA (Kajigaya et al., 1991), and instead
requires messages in which the VP-1 initiation codon
has been lost by a splicing event. This observation would
strongly suggest that B19 messages, like the overwhelm-
ing majority of cellular messages, only express their first
functional open-reading frame. If this holds true, then
usage of the splice site as reported here might be ex-
pected to effectively block translation of the viral capsid
proteins as well as the 11-kDa protein. Such a result
would come about if the small first fusion ORF were
efficiently recognized by ribosomal machinery. Given that
this ORF utilizes the ribosome binding site and initiation
codon of the well expressed viral NS-1 protein, it would
be surprising if these same initiation signals were not
recognized in their new fusion context.
Based on these observations, we propose a model
whereby in some nonpermissive cell types, host RNA
splicing machinery does not recognize the previously
reported canonical GT splice donor at nt 406 but instead
chooses an unusual CT donor at nt 441. Usage of this in
conjunction with the nt 2030 acceptor as previously iden-
tified in the majority of spliced viral transcripts function-
ally inactivates the viral structural genes and effectively
blocks production of progeny virions. As examined by
Northern blot analysis, all viral transcript families would
be indistinguishable from those of a permissive cell line,
as the total difference in length between these aberrantly
spliced messages and the productive ones is 35 nucle-
otides and would not be differentiated from transcript
size variation due to differences in polyadenylation. In-
triguingly, there exists in the literature very strong evi-
dence in support of this hypothesis. In particular, Leruez
et al. showed that in the UT7/EPO megakaryoblastic cell
line (similar to the MB-02 cell line examined here) B19
can enter cells and that as detected by hybridization, all
viral message families are produced as a consequence;
however, while NS-1 protein is expressed, viral capsid
gene products were not detectable in this study (Leruez
et al., 1994).
In our study, we do observe a very small number of
viral RT-PCR products of the sizes expected from the
previous transcription maps (Fig. 1, lanes 4 and 5). We
suspect that this accounts for the “semipermissivity” of
the MB-02 cell line, as a small percentage of primary
transcripts are processed as expected and can give rise
to functional capsid messages. We do not believe the
difference in band intensities are due to preferential
SPLICING PATTERN IN PARVOVIRamplification of our product due to its length, as the size
differences are very small and one of the predictedproducts of previously reported splice junctions is
shorter than our observed major product (see Table 1,
2030 acceptor).
Our observation of a CT splice donor is uncommon,
being to our knowledge only the second report of such a
dinucleotide functioning in this manner (French et al.,
1999) and the first report of a CT-AG acceptor/donor pair.
Comparison of the flanking sequences of our observed
splice donor (AG/CTATTT) with that of the common spli-
ceosomal U2 target of (AG/GTRAGT), the less common
U12-type introns (/ATATCTT), and that of the only previ-
ously published report of a CT donor (AC/CTGGGA)
[where R is any purine, /indicates the splice site, and
invariant residues are indicated in boldface; DNA se-
quence corresponding to RNA of message given]
(French et al., 1999; Stephens et al., 1992) shows a poor
match to any of them and suggests that a novel splicing
factor or pathway may be involved. Interestingly, the
sequence flanking the nt 406 splice donor previously
reported for this intron (AG/GTATTT) varies from our ob-
served donor site only at the 11 position relative to the
splice site. This conservation suggests that in both
cases B19 may be utilizing an uncharacterized splicing
motif; whether this requires specific host factors and/or
cis-acting elements remote from the splice junction is
something which further studies will be required to re-
solve. An intriguing possibility of using B19 with its small
genomic size and genetic simplicity to study this unusual
splicing suggests itself.
If our proposed mechanism is indeed a determining
factor for viral tropism, it clearly cannot explain B19’s
inability to replicate in the nonpermissive cells systems
where the mRNA splice junctions were previously
mapped; in these cases the block to viral replication
must arise via a mechanism such as the interference of
capsid protein message’s 39 UTR with translation as
demonstrated by Pallier et al. (1997). As these cell types
(COS-7, HeLa) are however more distant from the native
host cell of the virus than are such erythroid lineage cells
as MB-02, K562, and UT7, we believe that the mechanism
we propose here is the crucial one in restricting viral
tropism among bone-marrow-derived cells. Experiments
to further validate our findings by examination for expres-
sion of the putative 34-residue NS-1/7.5-kDa fusion prod-
uct at the expense of capsid proteins are currently on-
going and should help to resolve outstanding questions
regarding the influence of different mechanisms for host-
range restriction in B19.
MATERIALS AND METHODS
Cell culture. The human megakaryoblastoid cell line
MB-02 (Munshi et al., 1993) (a gift of Doris Morgan,
Hahnemann University, U.S.A.) was cultured in RPMI
2899 RESTRICTS ITS HOST RANGE1640 supplemented with glutamine, penicillin, streptomy-
cin, gentamicin (Sigma-Aldrich Co., St. Louis, MO; 20
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¨ D-VENmg/ml), GM-CSF (Boehringer Mannheim Biochemica,
Mannheim Germany; 200 U/ml), and 10% fetal calf serum
(GIBCO BRL, Gaithersburg, MD) at 37°C and 5% CO2.
Viral infection and RNA isolation. Infectious virus was
in the form of serum from a B19-infected patient during
the viremic phase (a gift of Bernard Cohen, PHLS, Colin-
dale, UK) and containing approximately 1013 genomes/
ml. MB-02 cells were induced to erythroid differentiation
by addition of Erythropoietin (Epo, Boehringer Mann-
heim, 4 U/ml) and stem cell factor (SCF, Boehringer
Mannheim, 25 ng/ml) to the culture media 6 days prior to
addition of 0.02–0.1 ml infectious virus (approximate
.o.i. 0.1–0.5). No significant differences were observed
etween results obtained from infections done with dif-
erent viral doses. Infections were allowed to proceed for
days prior to isolation of total culture RNA by Trizol
eagent (GIBCO BRL) in accordance with the supplier’s
nstructions. RNA isolates were resuspended in a final
olume of 30 ml per each 1.5 ml original cell culture.
RT-PCR and PCR. RT-PCR was performed with the
Titan one-tube system (Boehringer Mannheim) as per
supplier’s instructions, using 5 ml of RNA extract as
template per reaction. For B19 transcripts, the primer pair
B19L2 (59-GCTGTTTTTTGTGAGCTAACTAAC-39) and
B19S2O (59-ACTGGTCCCGGGGATG-39) were used and
cycled as follows: 42°C for 30 min, 94°C for 2 min, 10
cycles of (94°C for 30 s, 46°C for 30 s, and 68°C for 45 s),
25 cycles of (94°C for 30 s, 46°C for 30 s, and 68°C for
50 s), 68°C for 3 min, and then held at 15°C prior to
subsequent processing. For retinoblastoma transcripts,
the primer pair Rb1 (59-CTCACCTCCCATGTTGCTCA-39)
and Rb2O (59-CTCATCTATATTACATTCATGTTCTTTAC-39)
were used and cycled as for the B19 messages except
that all annealing steps (46°C, above) were conducted at
51°C.
Seminested second-round PCR amplifications of the
products of the RT-PCR were performed with Amplitaq
Gold polymerase (Perkin-Elmer, Branchburg, NJ) as per
the supplier’s general instructions. Briefly, for B19 prod-
ucts, 2 ml of B19 RT-PCR product was used as template
n a 50-ml reaction containing 1X supplier’s buffer, 200
mM dNTPs, 0.5 mM each of primers B19L2 and B19S2I
(59-GGCGTACTAGAGCGCGG-39), and 1.25 U of polymer-
ase. Reactions were thermocycled as follows: 95°C for
10 min, 40 cycles of (95°C for 30 s, 49°C for 30 s, 72°C
for 20 s), cooled to 15°C for 1 min, and then allowed to
rest at ambient temperature prior to analysis. For retino-
blastoma products, the same protocol was followed with
primers Rb1 and Rb2I (59-ATTTTCTAGTTGTTTTGC-
TATCCG-39) being used in place of the B19-specific prim-
ers.
B19 DNA in viremic serum extracts was detected by
PCR using Amplitaq Gold polymerase and primers p8f
(59-TGTGCTTACCTGTCTGGATTG-39) and p5r (59-AGGCT-
290 BRUNSTEIN, SODERLUNTGTGTAAGTCTTCAC-39) (So¨derlund et al., 1997). Vol-
umes and reagent concentrations were as per the semi-nested PCR above, and thermocycling was performed as
95°C for 10 min, 40 cycles of (94°C for 15 s, 55°C for 30 s,
72°C for 40 s), 72°C for 5 min, and then held at 4°C
before further processing.
Serum to be used as template directly for PCR and
RT-PCR was prepared by heating 5-ml samples of serum
iluted 1/100 in TE, pH 8, to 94°C for 5 min prior to
ddition to PCR or RT-PCR.
DNA sequencing. DNA sequencing was conducted by
n in-house sequencing facility (Haartman Institute, Uni-
ersity of Helsinki), utilizing ABI instruments and dye-
erminator chemistry.
RNase A digestions. Five-microliter aliquots of total
ellular RNA extract were mixed with four ml of TE, pH
8.0, buffer and 1 ml (2.8 Kuntz units) of DNAse-free RNase
(Sigma-Aldrich) and allowed to digest for 30 min at
oom temperature. Control RNA samples for these ex-
eriments were mixed with 5 ml of TE, pH 8.0, and
llowed to sit at room temperature for 30 min, without the
ddition of RNase A.
Direct cloning of B19 partial genome. The majority of
he B19 genome present in our infectious serum was
irectly cloned briefly as follows. One hundred microli-
ers of the infectious serum was mixed with proteinase K
uffer and subjected to overnight proteinase K digestion.
iberated sample DNA was purified with the Prep-A-
ene kit (BioRad Laboratories, Hercules, CA), and posi-
ive and negative polarity viral genomes were allowed to
nneal at room temperature. This DNA isolate was di-
ested with BssHII (New England Biolabs, Beverly, MA)
nd ligated to BssHII-digested, dephosphorylated Litmus
9 vector (New England Biolabs). Ligation products were
ransformed into competent Escherichia coli (strain
H5a) and transformants selected on media containing
mpicillin. Resulting clones containing the B19 genome
inus the extreme hairpin termini were selected based
n restriction digest and partial sequence analysis.
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